Search
Vyne Therapeutics Inc
VYNEAdd to Watchlist
0.681USD
+0.030+4.66%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
22.71MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+4.66%
5 Days
+4.77%
1 Month
-0.13%
6 Months
+17.39%
Year to Date
+17.39%
1 Year
-58.73%
Key Figures
0.650Open
0.695High
692.53KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.08%Turnover Ratio
0.651Prev. Close
0.650Low
382.17KTurnover
LossP/E Static
0.92P/B
0.00%Div Yield TTM
-52.78%ROA
1.96052wk High
6.11Volume Ratio
-39.83MNet Profit
33.35MShares
-0.5012EPS TTM
2.01Beta
-63.16%ROE
0.28152wk Low
6.90%Amplitude
100.00%Gross Margin
22.71MMarket Cap
-0.90Reward/Risk
4.18%Risk Rate
TradingKey Stock Score of Vyne Therapeutics Inc
Currency: USD Updated: 2026-06-30Key Insights
Vyne Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 206 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vyne Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Vyne Therapeutics Inc Highlights
StrengthsRisks
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 34.43% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 570.00K.
Undervalued
The company’s latest PE is -1.30, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 11.08M shares, decreasing 13.12% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 15.19K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
2.000
Target Price
+207.36%
Upside Space
Vyne Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Vyne Therapeutics Inc Info
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Ticker SymbolVYNE
CompanyVyne Therapeutics Inc
CEODomzalski (David)
Websitehttps://vynetherapeutics.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
FAQs
What is the current price of Vyne Therapeutics Inc (VYNE)?
The current price of Vyne Therapeutics Inc (VYNE) is 0.65.
What is the symbol of Vyne Therapeutics Inc?
The ticker symbol of Vyne Therapeutics Inc is VYNE.
What is the 52-week high of Vyne Therapeutics Inc?
The 52-week high of Vyne Therapeutics Inc is 1.96.
What is the 52-week low of Vyne Therapeutics Inc?
The 52-week low of Vyne Therapeutics Inc is 0.28.
What is the market capitalization of Vyne Therapeutics Inc?
The market capitalization of Vyne Therapeutics Inc is 21.62M.
Is Vyne Therapeutics Inc (VYNE) currently rated as Buy, Hold, or Sell?
According to analysts, Vyne Therapeutics Inc (VYNE) has an overall rating of Buy, with a price target of 2.00.
What is the Earnings Per Share (EPS TTM) of Vyne Therapeutics Inc (VYNE)?
The Earnings Per Share (EPS TTM) of Vyne Therapeutics Inc (VYNE) is -0.62.